DDInter112 DDInter1435
Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV).
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Aprepitant {u} (Compound) resembles {v} (Compound) Fosaprepitant
Aprepitant {u} (Compound) binds {v} (Gene) CYP1A2
Aprepitant {u} (Compound) palliates {v} (Disease) colon cancer
Aprepitant {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Aprepitant {u} (Compound) causes {v} (Side Effect) Myocardial infarction
Aprepitant {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cannabidiol
Aprepitant {u} may cause a minor interaction that can limit clinical effects when taken with {v} Citalopram
Aprepitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Toremifene
Aprepitant {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Aprepitant {u} may lead to a major life threatening interaction when taken with {v} Deflazacort
Aprepitant (Compound) resembles Fosaprepitant (Compound)
Aprepitant (Compound) binds CYP1A2 (Gene)
Aprepitant (Compound) palliates colon cancer (Disease)
Aprepitant (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class)
Aprepitant (Compound) causes Myocardial infarction (Side Effect)
Aprepitant may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Aprepitant may cause a minor interaction that can limit clinical effects when taken with Citalopram
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Toremifene
Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Aprepitant may lead to a major life threatening interaction when taken with Deflazacort